NCT07052838View on ClinicalTrials.gov

Efficacy and Safety of HSK392975 in Anti-C5 Treated PNH Patients With Anemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

December 25, 2025

Study Completion Date

January 8, 2026

Conditions
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Interventions
DRUG

HSK39297 tablets

200mg QD

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of Nanjing Medical University, Nanjing

RECRUITING

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY